Free Trial

Virtu Financial LLC Invests $271,000 in GRAIL, Inc. (NASDAQ:GRAL)

GRAIL logo with Medical background

Key Points

  • Virtu Financial LLC invested approximately $271,000 in GRAIL, acquiring 10,600 shares during the first quarter of the year.
  • GRAIL reported a quarterly loss of ($3.18) EPS, missing analysts' expectations, with revenue of $35.54 million for the quarter.
  • Major shareholder Chun R. Ding sold 339,800 shares of GRAIL stock, resulting in a 9.32% decrease in their stake in the company.
  • Looking to export and analyze GRAIL data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

Virtu Financial LLC bought a new position in shares of GRAIL, Inc. (NASDAQ:GRAL - Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor bought 10,600 shares of the company's stock, valued at approximately $271,000.

Several other large investors have also made changes to their positions in GRAL. LPL Financial LLC acquired a new position in shares of GRAIL during the 4th quarter worth approximately $244,000. Alliancebernstein L.P. purchased a new stake in shares of GRAIL during the fourth quarter worth approximately $250,000. Geode Capital Management LLC purchased a new stake in shares of GRAIL during the fourth quarter worth approximately $7,920,000. Wells Fargo & Company MN purchased a new stake in shares of GRAIL during the fourth quarter worth approximately $90,000. Finally, Envestnet Asset Management Inc. purchased a new stake in shares of GRAIL during the fourth quarter worth approximately $337,000.

GRAIL Stock Performance

Shares of GRAL opened at $32.43 on Friday. GRAIL, Inc. has a one year low of $12.33 and a one year high of $63.99. The stock has a market capitalization of $1.17 billion, a price-to-earnings ratio of -2.47 and a beta of 3.26. The stock has a 50 day moving average price of $40.12 and a 200 day moving average price of $36.23.

GRAIL (NASDAQ:GRAL - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($3.18) EPS for the quarter, missing the consensus estimate of ($3.14) by ($0.04). GRAIL had a negative return on equity of 16.64% and a negative net margin of 329.86%. The firm had revenue of $35.54 million for the quarter, compared to analysts' expectations of $37.57 million. On average, analysts predict that GRAIL, Inc. will post -15.15 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group boosted their price target on GRAIL from $32.00 to $43.00 and gave the stock a "buy" rating in a research report on Wednesday, May 14th.

Read Our Latest Analysis on GRAL

Insider Buying and Selling at GRAIL

In other GRAIL news, major shareholder Chun R. Ding sold 339,800 shares of the company's stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $49.53, for a total value of $16,830,294.00. Following the completion of the sale, the insider directly owned 3,305,055 shares in the company, valued at $163,699,374.15. This represents a 9.32% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, President Joshua J. Ofman sold 9,692 shares of the company's stock in a transaction on Monday, June 30th. The shares were sold at an average price of $52.00, for a total value of $503,984.00. Following the completion of the sale, the president owned 492,076 shares of the company's stock, valued at approximately $25,587,952. The trade was a 1.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 357,492 shares of company stock worth $17,645,718 in the last three months. 1.85% of the stock is owned by corporate insiders.

About GRAIL

(Free Report)

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.

Read More

Want to see what other hedge funds are holding GRAL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GRAIL, Inc. (NASDAQ:GRAL - Free Report).

Institutional Ownership by Quarter for GRAIL (NASDAQ:GRAL)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in GRAIL Right Now?

Before you consider GRAIL, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GRAIL wasn't on the list.

While GRAIL currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Palantir’s Soaring Valuation—Justified or Overhyped?
3 Stocks With Explosive Upside
September Slowdown: 3 Stocks to Buy When the Pullback Comes

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines